Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.
Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ, Kelly WK, Sternberg CN, Luo J, Lujambio A, Cordon-Cardo C, Alvarez-Fernandez M, Malumbres M, Huang H, Ertel A, Domingo-Domenech J, Rodriguez-Bravo V.
Dhital B, et al. Among authors: kirthika p.
Cell Rep Med. 2023 Feb 21;4(2):100937. doi: 10.1016/j.xcrm.2023.100937. Epub 2023 Feb 13.
Cell Rep Med. 2023.
PMID: 36787737
Free PMC article.